Immune System Peptides

Immune-modulating peptides represent a diverse group of compounds that influence the function of the innate and adaptive immune systems. Many of these peptides are derived from or inspired by thymic hormones, reflecting the thymus gland's critical role in immune system maturation and T-cell development.

Thymosin alpha-1 is the most clinically advanced immunomodulatory peptide, approved in over 35 countries for hepatitis B, hepatitis C, and immune enhancement, though it lacks FDA approval. Thymosin beta-4, primarily known for tissue repair, also possesses significant immunomodulatory properties. Thymalin, a polypeptide complex extracted from bovine thymus, has been approved in Russia since the 1980s, while immunofan is a synthetic hexapeptide immunomodulator also approved in Russia. Pidotimod is a synthetic dipeptide immunostimulant approved in several European and Asian countries for recurrent respiratory infections. KPV, the C-terminal tripeptide of alpha-MSH, demonstrates anti-inflammatory activity through NF-kappaB inhibition.

A significant portion of the clinical evidence for immune peptides originates from Russian research groups, which warrants additional scrutiny when evaluating the strength of the evidence base. Western clinical trials remain limited for several compounds in this category.